

Synthesis and Biological Activity of New Derivatives of 6-chloro-5-((4-chlorophenyl)diazenyl)pyrimidine-2,4-diamine and 4-chloro-6-methoxy-*N,N*-dimethylpyrimidin-2-amine

NADHIR NAJIMABDULLAH JAFAR^{1*}, HUSSEIN OLEIWI MUTTALEB AL-DAHMOUSHI²,
AYAD MOHAMMED JEBURALMAMOORI², NOOR SALMAN KADHIM AL-KHAFAJII³
and NAJIMABOD AL-MASOUDI³

¹Department of Chemistry, Babylon University, College of science, Babylon, Iraq.

²Department of Biology, Babylon University, College of Science, Babylon, Iraq.

³Department of chemistry, Basrah university, College of Science, Basrah, Iraq.

DOI: <http://dx.doi.org/10.13005/bpj/442>

(Received: November 04, 2013; Accepted: December 20, 2013)

ABSTRACT

6-chloro-5-((4-chlorophenyl)diazenyl)pyrimidine-2,4-diamine and 4-chloro-6-methoxy-*N,N*-dimethylpyrimidin-2-amine has been used as precursors for the synthesis of new pyrimidine derivatives, employing Suzuki cross-coupling reaction. Thus, treatment of pyrimidine derivative with various arylboronic acids in the presence of palladium tetraacetate, PhP_3 and Na_2CO_3 in refluxing *n*-propanol afforded the target compounds. The synthesis was supported by spectroanalytical techniques. The synthesized compounds have been screened for their inhibitory activity against some microbial, the results were showed that among gram positive isolates only (1/10) isolates of *S. aureus* and (3/10) isolates of *S. saprophyticus* were sensitive for compound 13, while (1/10) isolates of *S. aureus* and (1/10) isolates of *S. saprophyticus* were sensitive for compound 4. All isolates of *S. pyogenes* were resisting to all compounds, among gram negative bacterial isolates only (2/10) isolates of *E. coli* and (1/10) isolates of *K. pneumoniae* were sensitive to compound 4. Concerning the antifungal effects of compounds 3, 4, 5, 13, 14, 15 the results revealed that, all *C. albicans* and *C. glabrata* isolate were resist these compounds.

Key words: Pyrimidine, arylboronic acid, synthesis, Suzuki, gram positive.

INTRODUCTION

Pyrimidine is a prominent member of the diazine family of heterocyclics. It is found throughout nature as a component of nucleic acids, nucleotides and corresponding nucleosides. Pyrimidine was first isolated by Gabriel and Colman in 1899¹. Pyrimidine represents one of the most active class of compounds possessing wide spectrum of biological activity viz. significant in vitro activity against unrelated DNA and RNA, viruses including polio herpes viruses, diuretic, antitumor, anti HIV, cardiovascular². Methoprim, 5-(3,4,5-trimethoxybenzyl) pyrimidine-2,4-diamine (**1**)³, is a potent and interesting pyrimidine analogue was used, since 1980, in combination with sulfamethoxazole as a bacteriostatic antibiotic (Co-trimoxazole) and

mainly prescribed in the treatment of urinary tract infections and *Pneumocystis jirovecii* pneumonia, the most prevalent opportunistic microorganisms afflicting individuals with HIV positive patients.

Here cited compounds 1,2,3

The biodynamic property of the pyrimidine ring system prompted us to account for their pharmacological properties as antimicrobials acting against microorganisms⁴. In addition to this, pyrimidines ring is also found in vitamin B1, barbituric acid (2,4,6-trihydroxy pyrimidine) and its several derivatives e.g. Veranal², which are used as hypnotics⁵. In 1957, Heidelberger and Duschinsky⁶ had discovered 5-fluorouracil (5FU) **3** as a potential drug for tumor inhibition in mice and till update; this drug is used for treatment of cancer, in general.

RESULT AND DISCUSSION

Chemistry

Synthesis of 5-azoaryl-4-thioalkyl- and 4-benzylhydrazinyl-pyrimidines.

Synthesis

The azo-pyrimidine derivative 2 have been prepared previously by Al-Masoudi *et al.*⁷ from the commercially available 2,6-diamino-4-chloropyrimidine 1, and selected in our synthetic targets as a starting material for the synthesis of various pyrimidine analogs. Thus, treatment of 1 with *p*-chlorophenyldiazonium salt, prepared from reaction of *p*-chloroaniline with NaNO₂ and HCl at 0-5°C, afforded 2,6-diamino-4-(*p*-chlorophenyl-azo)-4-chloropyrimidine 2. Nucleophilic substitution with primary and secondary aliphatic amines, as well as O- and S-nucleophiles (phenoxide and thiophenoxide ions), which are formed *in situ* in the reactions of phenols and thiophenols with bases, has been reported to be successful to some extent and well known [1-5]. Therefore, the presence of azo group at position 5 of compound 2 would facilitate the nucleophilic replacement of chloro group at position 4 by S-nucleophiles and amines. Treatment of 2 with NaSPH or NaSEt in DMF afforded, via nucleophilic displacements of the chlorine group, 3 and 4 in 89 and 90% yield, respectively. Similarly, reaction of 2 with benzylhydrazine afforded compound 5 in 88% yields as shown in Scheme 1.

¹H and ¹³C NMR study

Structures of compounds 3-5 were assigned by the ¹H and ¹³C NMR spectra. The ¹H NMR spectra showed rather similar patterns for the phenyl and ethyl protons, while the singlets at δ = 4.31-3.84 ppm was attributed to methylene of the benzylhydrazine group. The methylene protons (SCH₂) of compound 4 appeared at δ 3.26 (J = 7.1 Hz) as a quartet, while methyl protons (SCH₃) appeared as a triplet at δ = 1.29 ppm (J = 7.1 Hz). The aromatic protons H-3 and H-5 of 3 resonated at δ = 7.78 ppm as a doublet (J = 7.0 Hz), while H-2 and H-6 appeared as a doublet at δ = 7.54 ppm (J = 7.0 Hz). C₆-NH₂ and C₂-NH₂ protons resonated at δ = 9.25 and 8.10 ppm as two doublets (J = 5.0 and 5.1 Hz), respectively. The aromatic protons of 4 resonated in the range δ = 7.90-7.80 ppm as a multiplet, while C₆-NH₂ and C₂-NH₂ protons appeared at δ = 9.25 and 6.88 ppm as two broad singlets, respectively. In ¹³C NMR spectra

of 3 and 4, C-4 of the pyrimidine ring resonated at δ = 182.1 and δ = 164.7 ppm, respectively, while C-2, C-5 and C-6 resonated at the regions (δ 164.6, 160.5 ppm), (δ = 118.5, 118.7 ppm) and (δ = 155.4, 155.9 ppm), respectively. The resonances at the regions δ = 166.9-161.0 ppm were attributed to C-4 and C-2 of 5, while, the resonances at δ = 104.7 and 105.5 ppm were assigned to C-5. The S-ethyl group of compound 4 were resonated at δ = 14.5 ppm (CH₂ carbon atom) and δ = 23.0 ppm (CH₃ carbon atom).

Figure 1 shows the resonances of C-2, C-4 and C-6 of compounds 3-5 in comparison for those of the 4-chloro compound 1. The resonance of C-4 of 184 at δ = 182.1 ppm shifted ~ 50 ppm, whereas the resonance of C-4 of 4 and 5 at δ = 164.7 ppm with shift ~ 33 ppm. These shifts in the ¹³C NMR resonances are indicative of chlorine replacement at C-4 of compound 1 by the thioalkyl and hydrazinophenyl groups.

Synthesis of 5-azo-biaryl-4-benzylhydrazinyl-pyrimidines

Synthesis

The use of catalytic cross-coupling methodologies for preparing aryl functionalized heterocycles with pharmaceutical, agrochemical, materials and supramolecular applications is a burgeoning field of study⁸. In particular, the so-called Suzuki reaction^{9-11, 12}, which involves palladium catalyzed cross coupling of heteroaryl-halides with aryl boronic acids, has received considerable recent attention. We are particularly interested in exploiting the versatility of the Suzuki cross-coupling procedure to prepare new 5-azoaryl and azobiaryl-pyrimidine analogues with the aim to evaluate their biological inhibition activity.

Treatment of 5 with arylboronic acids: *p*-fluorophenyl- and 3,4-dimethoxyphenylboronic acids, 16 and 9, respectively by applying Suzuki cross-coupling reaction, in the presence of palladium tetracetate / triphenylphosphine and Na₂CO₃ in hot *n*-propanol afforded 2,6-diamino-4-(2-benzylhydrazinyl)-5-(4'-fluoro-[1,1'-biphenyl]-4-yl)pyrimidine 7 and 4,6-diamino-4-(2-benzylhydrazinyl)-5-(3',4'-dimethoxy[1,1'-biphenyl]-4-yl)pyrimidine 9 in 78 and 87% yield, respectively (Scheme 2).

¹H and ¹³C NMR Study

Structures of **7** and **9** were analysed from the ¹H and ¹³C NMR spectra. The ¹H NMR spectra showed rather similar patterns for the phenyl protons. The doublets at $\delta=4.31$ and 4.32 ppm were assigned to methylene protons of the benzylhydrazine group ($J = 5.5$ and 5.1 Hz), respectively. C₆-NH₂ protons were appeared as broad singlets at $\delta = 8.03$ and 9.41 respectively, while C₂-NH₂ together with 2×NH protons were resonated at the range $\delta = 7.82-7.67$ ppm, and $\delta = 7.68-7.46$ ppm, respectively, which disappeared on D₂O exchange. The multiplets at the ranges $d = 7.68-7.46$ ppm, and $d = 7.68-7.46$ ppm, were assigned to the aromatic protons for both compounds **7** and **9**, respectively. In the ¹³C NMR spectrum of **7**, C-4, C-2 and C-6 were resonated at $\delta = 166.9$, 162.1 and 152.2 ppm, respectively, whereas C-5 appeared at $\delta = 104.7$ ppm. C₄-F and C₁-F of the aromatic ring were appeared as doublets at $\delta = 161.1$ ppm ($J_{C,F} = 250$ Hz) and $d = 139.2$ ppm ($J_{C,F} = 2.4$ Hz). Other aromatic carbon atoms resonated at the ranged $d = 133.9-119.2$ ppm, while methylene carbon atom appeared at $\delta = 55.4$ ppm. The ¹³C NMR spectrum of **190** showed signals at $\delta = 164.5$, 161.0 and 155.8 ppm were attributed to C-4, C-2 and C-6 of the pyrimidine backbone. The aromatic protons appeared at the range $d = 131.9-122.9$ ppm, while C-5 of the pyrimidine ring resonated at $\delta = 105.5$ ppm. C-1' and C-4' of the azophenyl residue appeared at $\delta = 141.6$ ppm, whereas C₃'-OMe and C₄'-OMe resonated at $\delta = 149.6$ ppm. C-2'' and C-5'' of the 3,4-OMe₂-phenyl group oriented at $\delta = 113.5$ ppm, and signals at $\delta = 55.4$ ppm was assigned to methylene carbon.

Synthesis of 5-azobiaryl-4-arylpurimidines.**Synthesis**

Furthermore, treatment of **2** with arylboronic acid: 4-fluorophenyl- **6**, 3,4-dimethoxyphenyl- **9**, 3-fluorophenyl- **10** and 4-nitrophenylboronic **11** acids via Suzuki cross-coupling reactions in the presence of palladium tetracetate / triphenylphosphine and Na₂CO₃ in hot *n*-propanol furnished the triaryl-purimidines **12-15** (92-99% yield). (Scheme 3).

¹H and ¹³C NMR study

Structures of the newly synthesized compounds **12-15** were assigned by the ¹H and ¹³C NMR spectra. The ¹H NMR spectra showed rather similar pattern for the phenyl protons. The assignment

of protons and carbons of the **12-15** were deduced from comparison with those of compounds **7** and **8**. In the ¹H NMR spectrum of **12**, NH₂ protons at C-6 and C-2 of the pyrimidine ring were appeared as two broad singlets at $\delta = 9.43$ and 7.06 ppm, respectively. The aromatic protons resonated as a multiplet at the region $\delta = 8.05-7.31$ ppm, while the methoxy groups appeared as two singlets at $\delta = 3.83$ and 3.74 ppm, respectively. The ¹H NMR spectrum of **13** showed two broad singlet at $\delta = 9.00$ and 6.71 ppm were assigned to NH₂ protons at C-6 and C-2 of the pyrimidine ring, respectively, whereas the multiplet at the region $d = 7.73-7.65$ was attributed to the aromatic protons. In the ¹H NMR of **14**, NH₂ protons at C-2 and C-6 resonated at $\delta = 8.22$ and 7.68 ppm, respectively, while the aromatic protons appeared as a multiplet at the range $\delta = 7.65-7.23$ ppm. NH₂ protons at C-2 and C-6 of compound **15** were appeared as two broad singlets at $\delta = 9.24$ and 6.94 ppm, respectively, whereas the aromatic protons resonated at the region $\delta = 8.16-6.96$ ppm. In the ¹³C NMR spectra of compounds **12-15**, C-2, C-4 and C-6 of the pyrimidine backbone were resonated at the range $\delta = 168.1-163.7$ ppm, $d = 162.2-160.0$ ppm and $\delta = 160.9-155.7$ ppm, respectively. C-2'' bearing fluorine atom of the aromatic ring appeared at $\delta = 158.5$ ppm as a doublet ($J_{C,F} = 249$ Hz) due to its coupling with the fluorine atom. C-5 of the pyrimidine ring appeared at the range $\delta = 122.9-119.9$ ppm, while C-1'' and carbon atom bearing NO₂ group (C-4'') of the aromatic ring attached to the phenylazo residue resonated at $\delta = 150.9$ ppm. The signal at $\delta = 55.1$ ppm was assigned to the methoxy groups of compound **13**.

Synthesis of 6-aryl-N,N-dimethylamino-4-methoxypurimidines.**Synthesis**

2-amino-4-chloro-N,N-dimethyl pyrimidine **16** has been selected as a precursor for the synthesis of new pyrimidine derivatives, employing Suzuki cross-coupling reaction, to examine the Biological inhibition activity. Thus, treatment of **16** with various arylboronic acids *e.g.*: 3-boronobenzoic acid **17**, 2-fluoro- **18**, 5-formylfuran-2-yl- **19** and 4-nitrophenyl boronic acid **11** in the presence of palladium tetraacetate, PhP₃ and Na₂CO₃ in refluxing *n*-propanol afforded **20-23** in 91-46% yield (Scheme 4).

¹H and ¹³C NMR Study

The structures of 20-23 were determined from the ¹H, and ¹³C NMR spectra. The methyl protons (NMe₂) (6H) appeared as singlets at the range δ = 3.21-2.94 ppm, while H-5 of the pyrimidine ring resonated at the range δ = 6.89-6.61 ppm. The methoxy groups of compounds 20-23 were appeared at rang δ = 3.92-3.74 ppm. The aromatic protons of compound 20 were resonated at the range δ = 8.35-8.16 ppm. The aromatic protons of compound 21 were appeared at the range δ = 8.29-8.02 ppm, respectively. The CO₂H proton of 21 was resonated as a singlet at δ = 10.45 ppm. The two multiplets at the ranges δ = 7.81-7.43 and 7.63 ppm were assigned to the aromatic protons of compounds 22. The ¹H NMR spectrum of 23 showed a singlet at δ = 10.54 ppm assigned to the aldehyde protons, whereas the doublet at δ = 8.58 ppm attributed to H-4 of the furan backbone (J = 5.2 Hz). H-3 of the furan ring appeared as a doublet at δ = 7.96 ppm (J = 5.2 Hz).

The ¹³C NMR spectra of 20-23 contained similar resonance signals of the pyrimidine carbons ring C2 – C6, as well as the methoxy and Nme₂ carbons. Carbon atoms of methoxy and Nme₂ pyrimidine ring of compounds 20-23 resonated at the ranges δ = 53.8-53.4 ppm and δ = 37.0-36.4 ppm, respectively. In the ¹³C NMR spectrum of 20, the signal at δ = 162.2 ppm was assigned to C-2 and C-6 of the pyrimidine ring, whereas signals at δ = 171.2 and 92.5 ppm were attributed to C-4 and C-5 of the same ring. 148.8 (C₄-NO₂) and other aromatic ring 1, 2 and 6, 3 and 5 were oriented at δ = 143.8, 128.4; and 124.1 ppm, respectively. The ¹³C NMR of compound 21 was characterized by the presence of downfield signal at δ = 173.4 ppm, assigned to the CO₂H group. C-2, C-4, C-5 and C-6 of the pyrimidine ring were oriented at δ = 161.7, 170.5, 91.4 and 162.7 ppm, respectively. The aromatic carbon atoms were appeared at the range 132.2-128.7 ppm. The ¹³C NMR spectrum of 22 showed signal at δ = 161.2, 171.8, 95.0 and 164.4 ppm were assigned to C-2, C-4, C-5 and C-6 of the pyrimidine backbone, respectively, whereas the doublet at δ = 156.6 ($J_{C_2,F}$ = 251 Hz) was attributed to the aromatic atom C-2 attached to fluorine atom. The multiplet at the range δ = 129.2-115.1 ppm was assigned to the aromatic carbon atoms and their couplings with the fluorine atom at C-2.

The ¹³C NMR of compound 23 characterized by the presence of the down-field signals at δ = 178.5 ppm were assigned to CHO group, C-2 of the pyrimidine ring were resonated at δ = 163.1 ppm, while C-4 appeared at δ = 170.3 ppm, C-5 of this compound resonated at δ = 102.3 ppm, whereas C-6 of the pyrimidine ring appeared at δ = 167.4 ppm. The signals at δ = 161.1, 111.8, 124.6 and 152.3 ppm were assigned to the carbon atoms 1-4 of the furan ring. The structure of 20 was further confirmed by the 2D NMR study (heteronuclear Single Quantum Correlation (HSQC))¹³. From the ¹H, ¹³C-HSQC spectrum of compound 20, the singlets of H-5, Ome and Nme₂ at δ = 6.72, 3.92 and 3.21 ppm were coupled to C-5, carbon of Ome and carbon of Nme₂ groups at δ = 92.5, 53.5 and 36.9 ppm, respectively. The multiplet for aromatic protons at δ = 8.35-8.16 ppm were coupled to the aromatic carbons C-3, C-5 and C-2, C-6 at δ = 128.4 and 124.1 ppm, respectively.

Biology

Microbiological resistance refers to nonsusceptibility of a fungus to an antifungal agent by in vitro susceptibility testing, in which the MIC of the drug exceeds the susceptibility breakpoint for that organism. Microbiological resistance can be primary (intrinsic) or secondary (acquired). Primary resistance is found naturally among certain fungi without prior exposure to the drug and emphasizes the importance of identification of fungal species from clinical specimens. Examples include resistance of *Candida krusei* to fluconazole and of *Cryptococcus neoformans* to echinocandins. Secondary resistance develops among previously susceptible strains after exposure to the antifungal agent and is usually dependent on altered gene expression. The development of fluconazole resistance among *Candida albicans* and *C. neoformans* strains illustrates this type of¹⁴. The four main mechanisms by which microorganisms exhibit resistance to antimicrobials are: Drug inactivation or modification, Alteration of target site, Alteration of metabolic pathway and Reduced drug accumulation: by decreasing drug permeability and/or increasing active efflux (pumping out) of the drugs across the cell surface¹⁵. Regarding the tested compounds of series 1, as depicted in table (1) and figure (2) the results of agar well diffusion method display that among gram positive isolates only (1/10) isolates of

S. aureus and (3/10) isolates of *S. saprophyticus* were sensitive for compound 13 while (1/10) isolates of *S. aureus* and (1/10) isolates of *S. saprophyticus* were sensitive for compound 4 with inhibition zone more than 12mm. All isolates of *S. pyogenes* were resisting to all compounds 3, 4, 5, 13, 14 and 15 as shown in figure (2).

Clinical resistance is defined as the failure to eradicate a fungal infection despite the administration of an antifungal agent with in vitro activity against the organism. Such failures can be attributed to a combination of factors related to the host, the antifungal agent, or the pathogen. Although clinical resistance cannot always be predicted, it highlights the importance of individualizing treatment strategies on the basis of the clinical situation¹⁶.

There are four major mechanisms of resistance to azoles have been described in *Candida* species: Decreased drug concentration. The first one is development of active efflux pumps results in decreased drug concentrations at the site of action. Efflux pumps are encoded in *Candida* species by 2 gene families of transporters: the CDR genes of the ATPbinding cassette super family, and the MDR genes of the major facilitator's class. The second mechanism is Target site alteration. It has been demonstrated that mutations in ERG11, the gene encoding for the target enzyme lanosterol C14a-demethylase, prevents binding of azoles to the enzymatic site¹⁷.

Among gram negative bacterial isolates only (2/10) isolates of *E. coli* and (1/10) isolates of *K. pneumoniae* were sensitive to compound 4 with inhibition zone more than 12mm. Concerning the antifungal effects of 3, 4, 5, 13, 14 and 15 compounds the results revealed that, all *C. albicans* and *C. glabrata* isolate were resist these compounds.

The third mechanism is up-regulation of target enzyme. Some *Candida* isolates with reduced susceptibility to azoles have higher intracellular concentrations of ERG11p than do azole-susceptible strains. The antifungal agent is, therefore, overwhelmed and routine therapeutic concentrations can no longer effectively inhibit ergosterol synthesis¹⁸. Target enzyme up-regulation can be achieved through gene amplification, increased transcription rate, or

decreased degradation of the gene product. The last mechanism of antifungal resistance is development of bypass pathways. Exposure to azole compounds results in depletion of ergosterol from the fungal membrane and accumulation of the toxic product 14a-methyl-3,6-diol, leading to growth arrest¹⁹.

As presented in figure (3) the susceptibility results of microbial isolates to 7, 8, 12, 20, 21, 22, and 23 synthetic organic compounds revealed that (2/10) isolates of each of the *S. aureus*, *S. saprophyticus* and *E. coli* while (1/10) isolates of each of *K. pneumoniae* and *C. albicans* were sensitive to compound 8 with inhibition zone more than 12mm. Only one isolate of *C. glabrata* was sensitive to compound 20 with inhibition zone more than 12mm.

We conclude that some of the synthetic organic compounds have both antibacterial and antifungal activity and can be used for treatments after achieving toxicity and safety tests. Structural modification of these compounds might optimize their biological activity by introducing diverse and potent functional group at pyrimidine back bone.

EXPERIMENTAL

Chemistry

General remarks

Melting points are uncorrected and were measured on a Stuart melting point apparatus (SMP30, England). The nuclear magnetic resonance data were obtained 400 and 600 MHz (¹H) and 150.91 MHz (¹³C) spectrometers (Avance III, Bruker, Germany), Tetramethylsilane TMS used as internal reference. The spectral data were reported in delta (δ) scale in ppm units relative to TMS reference line. Multiplicities (s = singlet, d = doublet, t = triplet, q = quartet and m = multiples). Heteronuclear assignments were verified by ¹H-¹³C HSQC experiments. Microanalytical data were obtained with a Vario, Elemental apparatus (Shimadzu, Japan). Thin layer chromatography (TLC) was carried out using TLC-silica plates GOF254 (0.2 mm) of the Merck Company. The detection was followed by UV-Lamp at 254 nm or through coloring with iodine. The chromatographic separations were carried out using silica gel (60-230 mesh). The ratio of the solvent and mixed mobile phases was given in volume ratio.

Solvents

Solvents were dried and purified by conventional methods prior to use. Acetone was dried and distilled prior to use from phosphorus pentoxide (P_2O_5). Chloroform and dichloromethane were dried and distilled over dry Calcium chloride, collected over magnesium sulphate then filtered over magnesium sulphate. All of these solvent obtained from Scharalau. But Hexane, Ethanol, Methanol, Propanol, DMF obtained from Thomas Baker (chemicals) limited. Whereas THF and ethyl acetate were obtained from a BDH Chemical Ltd (pode England).

Chemicals

6-chloro-5-((4-chlorophenyl) diazenyl) pyrimidine-2,4-diamine were given from Prof. Najim Al-Masoudi prepared by same procedure published in *J.Med.Chem*⁷.

6-chloro-1,3-dimethyl-5-nitropyrimidine-2,4-(1*H*,3*H*)-dione, 2,6-Diamino-4-chloro-pyrimidine and all arylboronic acids listed below were purchased from Sigma-Aldrich.

synthesis

Preparation of 2,6-diamono-4-chloro-5-*p*-chlorophenylazopyrimidine (2)

The compound was prepared by method described in reference [7] from the commercially available 2,6-diamino-4-chloropyrimidine **2** (2.55 g, 20 mmol) in 6N HCl (10 mL) and *p*-chlorophenyl diazonium salt [from $NaNO_2$ (1.38 g, 20 mmol) in water (6 mL) at 0 °C]. Yield: 78%, m.p. 267 °C, Lit. 268 °C.

2,6-Diamino-6-phenylthio-5-*p*-chlorophenylazo pyrimidine (3)

A solution of **2** (250 mg, 0.89 mmol) in benzene (20 mL) containing NaSPh (110 mg, 0.89 mmol) was heated under reflux. After for 8 h, the color of solution was changed into an yellow color, where the completion of reaction was monitored by TLC. After cooling, the solution was concentrated and left overnight at low temperature. The yellow crystals were collected and recrystallized from EOH to give **3** (281 mg, 89%), m.p. 237-238 °C. ¹H NMR (DMSO-*d*₆): δ= 9.25 (br s., 2H, C₆-NH₂); 7.90-7.30 (m, 9H, H_{arom}), 6.88 (br s., 2H, C₂-NH₂). ¹³C NMR (DMSO-*d*₆): δ= 182.1 (C-4); 164.6 (C-2); 155.4 (C-6); 139.8

(C_{arom}-Cl); 133.4 (C^{1'}_{arom}-S); 129.4, 129.3, 128.7, 128.3, 127.5, 125.4, 124.1, 122.9 (C_{arom}); 118.5 (C-5). Anal. calcd. For C₁₆H₁₃ClN₆S (356.83): C, 53.85; H, 3.67; N, 23.55. Found; C, 53.53; H, 3.54; N, 23.72.

2,6-Diamino-4-ethylthio-5-*p*-chlorophenylazopyrimidine (4)

Method was analogues to the proceeding procedure, using instead **2** (250 mg, 0.87 mmol) and NaSEt (74 mg, 0.887 mmol). Yield: 235 mg (90%), m.p. 267-268 °C. ¹H NMR (DMSO-*d*₆): δ = 9.25 (d, 2H, *J* = 5.0 Hz, C₆-NH₂); 8.10 (d, 2H, *J* = 5.1 Hz, C₂-NH₂); 7.78 (d, 2H, *J* = 7.0 Hz, H_{arom}-3 + H_{arom}-5); 7.54 (d, 2H, *J* = 7.0 Hz, H_{arom}-2 + H_{arom}-6). ¹³C NMR (DMSO-*d*₆): δ=164.7 (C-4); 161.2 (C-2); 155.9 (C-6); 133.5 (C_{arom}-Cl); 129.3, 123.3 (C_{arom}); 118.7 (C-5). Anal. calcd. For C₁₂H₁₃ClN₆S (308.79): C, 46.68; H, 4.24; N, 27.22. Found; C, 46.38; H, 4.18; N, 27.39.

2,6-Diamino-4-(2-benzylhydrazinyl)-5-*p*-chlorophenylazopyrimidine (5)

To a solution of **2** (1.0 g, 3.54 mmol) in EtOH (30 mL) was added benzylhydrazine hydrochloride (0.45 g, 2.84 mmol) and the mixture was heated under reflux for 2 h. After cooling, the orange solution was concentrated and left overnight at 0 °C. The orange crystals were filtered, and recrystallized from EtOH to give **8** (1.14 g, 88%), m.p. 211-215 °C. ¹H NMR (DMSO-*d*₆): δ = 9.31 (br s., 2H, C₆-NH₂), 9.00-8.96 (m, 2H, 2xNH); 8.26 (brs., 2H, C₄-NH₂); 7.99-7.35 (m, 9H, H_{arom}); 4.06 (s, 2H, CH₂). ¹³C NMR (DMSO-*d*₆): δ= 164.7 (C-4); 160.5 (C-2); 155.4 (C-6); 139.8 (C^{1'}_{phenylhydraz.}); 133.4 (C_{arom}-Cl); 129.3, 129.2, 128.4, 128.1 (C_{arom}); 103.8 (C-5); 53.6 (CH₂). Anal. calcd. For C₁₇H₁₇ClN₈ (368.82): C, 55.36; H, 4.65; N, 30.38. Found C, 55.36; H, 4.50; N, 30.21.

General procedure of Suzuki reaction for preparation of 7 and 12- 15

2,6-Diamino-4-(2-benzylhydrazinyl)-5-(4'-fluoro-[1,1'-biphenyl]-4-yl)pyrimidine (7)

A mixture of halopyrimidine and arylboronic acid in *n*-propanol (15 mL) was stirred for 15 min. To this mixture was added Pd(OAc)₄ (650 mg, 0.19 mmol), triphenylphosphine (498 mg, 0.19 mmol) and 2M aq. solution of Na₂CO₃ (3.5 mL). The reaction mixture was refluxed under nitrogen for 4-6 h and completion of reaction was monitored by TLC. After cooling, water was added (7 mL), followed by stirring for 5 min. The mixture was partitioned with

ethyl acetate (3×10 mL) and the combined organic layers were washed subsequently with 5% Na₂CO₃ solution (2×10 mL), brine solution (2×10 mL) and finally with water (10 mL). The organic phase was decolorized with charcoal, filtered and the filtrate was dried (Na₂SO₄), filtered through celite and evaporated to dryness to give, after purification, the desired product.

From **5** (70 mg, 0.19 mmol) and *p*-fluorophenylboronic acid **6** (27 mg, 0.19 mmol). Yield: 63 mg (78%), as a brown crystals, m.p. 180-182 °C (dec), R_f = 0.67 (eluent: ethyl acetate/hexane 3:2). ¹H NMR (DMSO-*d*₆): δ = 8.03 (br s., 2H, C₆-NH₂), 7.82-7.67 (m, 4H, C₂-NH₂+2xNH); 7.64-7.31 (m, 13H, H_{arom}); 4.31 (d, 2H, *J* = 5.5 Hz, CH₂). ¹³C NMR (DMSO-*d*₆): δ = 166.9 (C-4); 162.1 (C-2); 161.1 (d, *J*_{C₄^{ar},F} = 250 Hz, C₄^{ar}-F); 152.2 (C-6); 139.5 (C-4' + C¹_{phenylhydraz}); 139.2 (d, *J*_{C-1^{ar},F} = 2.4 Hz, C-1^{ar}); 133.9, 133.1, 131.9, 131.4, 129.2, 128.7, 128.6, 127.2, 119.2 (C_{arom}); 104.7 (C-5); 55.4 (CH₂). Anal. calcd. For C₂₃H₂₁FN₈ (428.46): C, 64.47; H, 4.94; N, 26.15. Found: C, 64.24; H, 4.90; N, 25.94.

2,6-Diamino-4-(3,4-dimethoxyphenyl)-5-(3,4-dimethoxy[1,1'-biphenyl]-4-yl) pyrimidine (**8**)

From **5** (122 mg, 0.40 mmol) and 3,4-dimethoxyphenylboronic acid **9** (155 mg, 0.85 mmol). Yield: 193 mg (92%), as a red crystals, m.p. 165-166 °C, R_f = 0.54 (eluent: ethyl acetate/hexane 3:2). ¹H NMR (DMSO-*d*₆): δ = 9.00 (br s, 2H, C₆-NH₂); 7.73-7.65 (m, 10H, H_{arom}); 6.71 (br s, 2H, C₂-NH₂); 3.83, 3.76, 3.74 (m, 12H, 4×OMe). ¹³C NMR (DMSO-*d*₆): δ = 163.7 (C-2); 161.7 (C-4), 160.9 (C-6), 151.8, 147.0 (4×C-OMe); 141.0 (C-1'); 131.9, 131.4, 131.3, 129.2, 128.7, 128.5 (C_{arom}); 122.9 (C-5); 113.5, 112.1, 110.3 (C_{arom}); 55.1 (4×OMe). Anal. calcd. for C₂₆H₂₆N₆O₄ (486.52): C, 64.19; H, 5.39; N, 17.27. Found: C, 64.56; H, 5.31; N, 17.20.

2,6-Diamino-4-(4-fluorophenyl)-5-(4-fluoro[1,1'-biphenyl]-4-yl) pyrimidine (**12**)

From **2** (86 mg, 0.30 mmol) and 4-Fluorophenylboronic acid **6** (85 mg, 0.60 mmol). Yield: 93 mg (76%), as a red crystals, m.p. 179-180 °C, R_f = 0.70 (eluent: ethyl acetate/hexane 2:1). ¹H NMR (DMSO-*d*₆): δ = 9.43 (br s, 2H, C₆-NH₂), 8.05-7.31 (m, 12H, H_{arom}); 7.06 (br s, 2H, C₂-NH₂). ¹³C NMR (DMSO-*d*₆): δ = 165.4 (C-2); 161.0 (m, C-4 + 2xC₄^{ar}-F); 155.9 (C-6); 139.7 (C-1'); 133.9, 133.1,

132.1, 131.45, 131.36, 130.67, 129.9, 127.2 (C_{arom}); 122.3 (C-5); 120.8, 116.2, 115.3 (C_{arom}-C + C_{arom}-e + C-3'' + C5''). Anal. calcd. For C₂₂H₁₆F₂N₆ (402.40): C, 65.66; H, 4.01; N, 20.88. Found: C, 65.42; H, 3.96; N, 20.65.

2,6-Diamino-4-(3,4-dimethoxyphenyl)-5-(3,4-dimethoxy[1,1'-biphenyl]-4-yl) pyrimidin (**13**)


From **2** (122 mg, 0.40 mmol) and 3,4-dimethoxyphenylboronic acid **9** (155 mg, 0.85 mmol). Yield: 193 mg (92%), as a red crystals, m.p. 165-166 °C, R_f = 0.54 (eluent: ethyl acetate/hexane 3:2). ¹H NMR (DMSO-*d*₆): δ = 9.00 (br s, 2H, C₆-NH₂); 7.73-7.65 (m, 10H, H_{arom}); 6.71 (br s, 2H, C₂-NH₂); 3.83, 3.76, 3.74 (m, 12H, 4×OMe). ¹³C NMR (DMSO-*d*₆): δ = 163.7 (C-2); 161.7 (C-4), 160.9 (C-6), 151.8, 147.0 (4×C-OMe); 141.0 (C-1'); 131.9, 131.4, 131.3, 129.2, 128.7, 128.5 (C_{arom}); 122.9 (C-5); 113.5, 112.1, 110.3 (C_{arom}); 55.1 (4×OMe). Anal. calcd. For C₂₆H₂₆N₆O₄ (486.52): C, 64.19; H, 5.39; N, 17.27. Found: C, 64.56; H, 5.31; N, 17.20.

2,6-Diamino-4-(2-benzylhydrazinyl)-5-(2'-fluoro[1,1'-biphenyl]-4-yl)pyrimidine (**14**)


From **5** (70 mg, 0.19 mmol) and *o*-fluorophenylboronic acid (27 mg, 0.19 mmol). Yield: 63 mg (78%), as a brown crystals, m.p. 180-182 °C (dec), R_f = 0.67 (eluent: ethyl acetate/hexane 3:2). ¹H NMR (DMSO-*d*₆): δ = 8.03 (br s., 2H, C₆-NH₂), 7.82-7.67 (m, 4H, C₂-NH₂+2xNH); 7.64-7.31 (m, 13H, H_{arom}); 4.31 (d, 2H, *J* = 5.5 Hz, CH₂). ¹³C NMR (DMSO-*d*₆): δ = 166.9 (C-4); 162.1 (C-2); 161.1 (d, *J*_{C₄^{ar},F} = 250 Hz, C₄^{ar}-F); 152.2 (C-6); 139.5 (C-4' + C¹_{phenylhydraz}); 139.2 (d, *J*_{C-1^{ar},F} = 2.4 Hz, C-1^{ar}); 133.9, 133.1, 131.9, 131.4, 129.2, 128.7, 128.6, 127.2, 119.2 (C_{arom}); 104.7 (C-5); 55.4 (CH₂). Anal. calcd. for C₂₃H₂₁FN₈ (428.46): C, 64.47; H, 4.94; N, 26.15. Found: C, 64.24; H, 4.90; N, 25.94.

2,6-Diamino-4-(4-nitrophenyl)-5-(4-nitro[1,1'-biphenyl]-4-yl)pyrimidine (**15**)


From **2** (213 mg, 0.75 mmol) and 4-nitrophenylboronic acid **11** (250 mg, 1.50 mmol). Yield: 323 mg, (94%), as a red crystals, m.p. 185-187 °C, R_f = 0.70 (eluent: ethyl acetate/hexane 2:1). ¹H NMR (DMSO-*d*₆): δ = 9.24 (s, 2H, C₆-NH₂); 8.16-6.96 (m, 12H, H_{arom}); 6.94 (s, 2H, C₂-NH₂). ¹³C NMR (DMSO-*d*₆): δ = 164.5 (C-2); 161.0 (C-4); 155.7 (C-6); 150.9 (C-1'' + 2xC₄^{ar}-NO₂); 133.2, 131.8, 131.2, 129.1, 126.0, 122.6, 121.9 (C_{arom}); 118.5 (C-5). Anal.



Scheme 1: Synthesis of compounds 3-5



Scheme 2: Synthesis of compounds 7 and 8



Scheme 3: Synthesis of compounds 12-15

calcd. For $C_{22}H_{16}N_8O_4$ (456.41): C, 57.89; H, 3.53; N, 24.55. Found: C, 57.76; H, 3.48; N, 24.71.

General procedure for preparation of 6-amino-4-methoxy-*N,N*-dimethyl-6-arylpyrimidines 20-23 via Suzuki reaction

A suspension of 2-amino-4-chloro-6-methoxy-*N,N*-dimethylpyrimidine 16 and arylboronic acid in *n*-propanol (15 mL), then it was stirring for 15 minute until the solid was dissolved. To this solution Pd(OAc)₂ (360 mg, 0.11 mmol), Ph₃P (128 mg, 0.49 mmol) and 2M aq. solution of Na₂CO₃ (4 mL) was added. The reaction mixture was refluxed under nitrogen for 4-8 h, and the reaction progress was monitored by TLC (eluent: ethyl acetate/ hexane 1:1). After cooling, the reaction mixture was filtered, and concentrated under vacuum. The solid product was filtered and washed with cold ether to give the desired product.

2-Amino-4-methoxy-*N,N*-dimethyl-6-(4-nitrophenyl)pyrimidine (20)

From **16** (100 mg, 0.53 mmol) and *p*-nitrophenylboronic acid **11** (89 mg, 0.53 mmol). Yield: 100 mg (68%), as a green crystals, m.p. 137-139 °C, $R_f = 0.40$. ¹H NMR (DMSO-*d*₆): $\delta = 8.35-8.16$ (m, 4H, H_{arom}); 6.72 (s, 1H, H-5), 3.92 (s, 3H, OMe), 3.21 (s, 6H, NMe₂). ¹³C NMR (DMSO-*d*₆): $\delta = 171.2$ (C-4); 162.2 (C-2 + C-6); 148.8 (C₄-NO₂); 143.8 (C_{arom}-1'); 128.4 (C_{arom}-2' + C_{arom}-6'); 124.1 (C_{arom}-3' + C_{arom}-5'); 92.5 (C-5); 53.5 (OMe); 36.9 (NMe₂). Anal. calcd. For C₁₃H₁₄N₄O₃ (274.28): C, 56.93; H, 5.14; N, 20.43. Found: C, 56.71; H, 5.02; N, 20.21.

3-(2-(*N,N*-Dimethylamino)-6-methoxypyrimidin-4-yl)benzoic acid (21)

From **16** (100 mg, 0.53 mmol), and 3-boronobenzoic acid **17** (88 mg, 0.53 mmol). Yield: 85 mg (59%), as a white powder, m.p. >300 °C (dec.), $R_f = 0.60$. ¹H NMR (DMSO-*d*₆): $\delta = 10.45$ (s, 1H, CO₂H); 8.29-8.02 (m, 4H, H_{arom}); 6.62 (s, 1H, H-5); 3.90 (s, 3H, C₄-OMe); 3.20 (s, 6H, NMe₂). ¹³C NMR (DMSO-*d*₆): $\delta = 173.4$ (CO₂H); 170.5 (C-4); 162.7 (C-6); 161.7 (C-2); 132.2, 130.9, 129.6, 129.1, 128.7 (C_{arom}); 91.4 (C-5); 52.8 (OMe); 36.3 (NMe₂). Anal. calcd. For C₁₄H₁₅N₃O₃ (273.29): C, 61.53; H, 5.53; N, 15.38. Found: C, 61.32; H, 5.41; N, 15.17.

2-Amino-4-(2-fluorophenyl)-6-methoxy-*N,N*-dimethylpyrimidine (22)

From **16** (100 mg, 0.53 mmol) and 2-(fluoro)

phenylboronic acid **18** (75 mg, 0.53 mmol). Yield: 96 mg, (73%), as a yellowish powder, m.p. 249-253 °C, $R_f = 0.48$. ¹H NMR (DMSO-*d*₆): $\delta = 7.81-7.43$ (m, 4H, H_{arom}); 6.82 (s, 1H, H-5); 3.82 (s, 3H, C₄-OMe); 3.13 (s, 6H, NMe₂). ¹³C NMR (DMSO-*d*₆): $\delta = 171.8$ (C-4); 164.4 (C-6); 161.1 (C-2); 156.6 (d, $J_{C_2,F} = 251$ Hz, C₂-F); 129.2, 129.1, 128.8, 127.5, 125.4, 122.9, 115.1 (m, $J_{C,F}$ couplings, C_{arom}); 95.0 (C-5); 53.5 (OMe); 36.8 (NMe₂). Anal. calcd. For C₁₃H₁₄FN₃O (247.27): C, 63.15; H, 5.71; N, 16.99. Found: C, 62.90; H, 5.65; N, 15.82.

5-(2-(Dimethylamino)-6-methoxypyrimidin-4-yl) furan-2-carbaldehyde (23)

From **16** (200 mg, 1.07 mmol) and (5-formyl-2-yl)boronic acid **19** (150 mg, 1.07 mmol). Yield: 177 mg (67%), as a pale brown powder, m.p. 248-250 °C (dec.), $R_f = 0.61$. ¹H NMR (DMSO-*d*₆): $\delta = 10.54$ (s, 1H, CHO); 8.58 (d, 1H, $J = 5.2$ Hz, H_{furan}-4'); 7.96 (d, 1H, $J = 5.2$ Hz, H_{furan}-3'); 6.83 (s, 1H, H-5); 4.25 (s, 3H, OMe); 2.94 (s, 6H, NMe₂). ¹³C NMR (DMSO-*d*₆): $\delta = 178.5$ (CHO); 170.3 (C-4); 167.4 (C-6); 163.1 (C-2); 161.1 (C_{furan}-1'); 152.3 (C-CHO); 124.6 (C_{furan}-3'); 111.8 (C_{furan}-2'); 102.3 (C-5); 53.8 (OMe); 38.1 (NMe₂). Anal. calcd. For C₁₂H₁₃N₃O₃ (274.25): C, 58.29; H, 5.30; N, 16.99. Found: C, 58.02; H, 5.22; N, 16.42.


Biology

Tested Microbes

The antimicrobial effects of the fourteen synthetic organic compounds (under test) were experimented on the different local pathogenic isolates of gram positive bacteria (10 isolates of *Staphylococcus aureus*, 10 isolates of *Staphylococcus saprophyticus* and 10 isolates of *Streptococcus pyogenes*), gram negative bacteria (10 isolates of *Escherichia coli*, 10 isolates of *Klebsiella pneumonia* and 10 isolates of *Pseudomonas aeruginosa*) and some of the clinically important yeast (10 isolates of *Candida albicans* and 10 isolates of *Candida glabrata*). All these isolates were gathered from the advanced microbiology lab, Biology departments in faculty of science- Babylon University, Iraq.

Well Diffusion Method

The synthetic organic compounds were used for studying their antibacterial activity. A loop full of the experimented isolates of bacteria or fungus was inoculated in 30 mL of Nutrient broth in a conical



Scheme 4: Synthesis of new pyrimidine derivatives 20-23 from 2-amino-4-chloro-N,Ndimethylpyrimidine 16




Fig. 1: The resonances of carbons 2, 4 and 6 in ^{13}C NMR spectra of compound 3-5 in comparison for those of the starting material 1




Fig. 2: Percentage of sensitive microbial isolates to 3,4,5,13,14 and 15 synthetic organic compounds




Fig. 3: Percentage of sensitive microbial isolates to 3, 4, 5, 13, 14 and 15 synthetic organic compounds

flask and incubated for 72 hrs to get active strain by using agar well diffusion method. Muller Hinton Agar (or Potato dextrose agar for fungus) was poured into Petri dishes. After solidification 0.25 ml of test strains were inoculated in the media separately. Care was taken to ensure proper homogenization. The experiment was performed under strict aseptic conditions. After the medium solidified, a well was made in the plates with sterile borer (5mm). The compound (50 μ l) was introduced into the well

and plates were incubated at 37°C for 72 hrs. All samples were tested in triplicates. Microbial growth was determined by measuring the diameter of zone of inhibition²⁰.

ACKNOWLEDGEMENTS

We thank Mr. U. Haunz and Miss A. Friemel of chemistry department, University of Konstanz, Germany for NMR experiments.

REFERENCES

- Gabriel. S.; Colman. J, *Ber. Dtsch. Chem. Ges.* **32**: 1536 (1899).
- Kappe. C. O. *Tetrahedron* **49**: 6937-6963 (1993) (review) .
- Stenbuck. P.; H. M. Hood, US Patent **62**: 3,049,544 (1962).

4. Kidwai. M.; Saxena. S.; Rastogi. S.; Venkataramanan. R. *Curr. Med.Chem.-Anti-Infect. Agents* **24**: 269-286 (2003).
5. Jain.M.K.;Sharnevsas.S.C.organic chemistry, III edition, 997-999 (2008).
6. Heidelberger. C.; Chaudhuri. N. K.; Danneberg.P.; Mooren. D.; Griesbach. L.; R., Duschinsky. R.; Schnitzer. J.; Plevin. E.; Scheiner. J. *Nature*, **179**: 663-666 (1957).
7. Fröhlich. L. G.;Kotsonis. P.;Traub. H.;Taghavi-Moghadam.S.; Al-Masoudi. N.; Strobel. H.;Matter.H.;Pfleiderer. H. W. *J. Med. Chem.*, **42**: 4108- 4121 (1999).
8. Stanforth. S. P. *Tetrahedron*, **54**: 263-303 (1998).
9. Miyaura.N.;Yamada.K.;Suzuki.A. *Tetrahedron Lett.*, **20**: 3437-3440 (1979).
10. Miyaura. N.; Suzuki. A. *Chem. Comm.*, **19**: 866-867 (1979).
11. Miyaura. N.; Suzuki. A. *Chem. Rev.*, **95**: 2457-2483 (1995).
12. Gribble. J. J. Li, G. W. *Palladium in Heterocyclic Chemistry; Tetrahedron Organic Chemistry Series*; Pergamon: Amsterdam, 20 (2000).
13. Davis. A. L.; Keeler J.; Laue. E. D.; Moskau. D. *J. Magn. Reson* , **98**: 207-216 (1992).
14. Marichal. P.; Koymans. L.;Willemsens. S.; *et al. Microbiology*; 145(Pt10): 2701–13 (1999).
15. Nikadio. X. Li, H. *Drug.*, **69**(12):1555–623 (2009).
16. Kanafani. Z.A.; Perfect. J.R. *Clinical Infectious Diseases.*, 46: 120–8 (2008).
17. Sanglard. D.; Bille. J. Washington, DC: ASM Press, 349–83 (2002).
18. Mellado. E.; Garcia-Effron. G.; Alcazar-Fuoli. L.; Cuenca-Estrella. M.; Rodriguez- Tudela. J.L.; *Antimicrob Agents Chemother.*, **48**: 2747–50 (2004).
19. Mellado. E.; Garcia-Effron. G.; Alcazar-Fuoli. L.; Cuenca-Estrella. M.; Rodriguez- Tudela. J.L. *Antimicrob Agents Chemother.* **51**: 1897–904 (2007).
20. Clinical and Laboratory Standards Institute (CLSI). Twentieth Informational Supplement. 2010, M100-S20; Vol. 30 No. 1 Replaces M100-S19 Vol. 29 No. 3: 1-157.